About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Statistics in Biopharmaceutical Research
›
top-articles
Statistics in Biopharmaceutical Research
1.3
(top 50%)
impact factor
699
(top 20%)
papers
4.3K
(top 20%)
citations
30
(top 20%)
h
-index
1.4
(top 50%)
extended IF
862
all documents
4.9K
doc citations
40
(top 20%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step Toward Pragmatism in Benefit:Risk Evaluation
Statistics in Biopharmaceutical Research
2016
93
2
Evaluation of Drug Combination Effect Using a Bliss Independence Dose–Response Surface Model
Statistics in Biopharmaceutical Research
2018
86
3
Multiple Testing in Group Sequential Trials Using Graphical Approaches
Statistics in Biopharmaceutical Research
2013
81
4
Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic
Statistics in Biopharmaceutical Research
2020
65
5
Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis
Statistics in Biopharmaceutical Research
2020
64
6
A Simulation Study to Compare New Adaptive Dose–Ranging Designs
Statistics in Biopharmaceutical Research
2010
58
7
Statistical Considerations on Subgroup Analysis in Clinical Trials
Statistics in Biopharmaceutical Research
2015
56
8
Meta-Analysis of Clinical Dose–Response in a Large Drug Development Portfolio
Statistics in Biopharmaceutical Research
2014
55
9
Responder Analyses—A PhRMA Position Paper
Statistics in Biopharmaceutical Research
2011
46
10
Estimands and Their Role in Clinical Trials
Statistics in Biopharmaceutical Research
2017
45
11
Personalized Medicine: Four Perspectives of Tailored Medicine
Statistics in Biopharmaceutical Research
2015
44
12
Statistical Design and Considerations of a Phase 3 Basket Trial for Simultaneous Investigation of Multiple Tumor Types in One Study
Statistics in Biopharmaceutical Research
2016
44
13
Chain Procedures: A Class of Flexible Closed Testing Procedures With Clinical Trial Applications
Statistics in Biopharmaceutical Research
2011
42
14
The Role of
p
-Values in Judging the Strength of Evidence and Realistic Replication Expectations
Statistics in Biopharmaceutical Research
2021
42
15
The ICH Q8 Definition of Design Space: A Comparison of the Overlapping Means and the Bayesian Predictive Approaches
Statistics in Biopharmaceutical Research
2010
41
16
Impact of Dose Selection Strategies Used in Phase II on the Probability of Success in Phase III
Statistics in Biopharmaceutical Research
2010
41
17
Causal Inference and Estimands in Clinical Trials
Statistics in Biopharmaceutical Research
2020
41
18
Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendations. White Paper of the PhRMA Working Group on Adaptive Dose-Ranging Studies
Statistics in Biopharmaceutical Research
2010
40
19
Machine learning for clinical trials in the era of COVID-19
Statistics in Biopharmaceutical Research
2020
40
20
Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19
Statistics in Biopharmaceutical Research
2020
40
21
Missing Data: Turning Guidance Into Action
Statistics in Biopharmaceutical Research
2013
39
22
On the Use of Co-Data in Clinical Trials
Statistics in Biopharmaceutical Research
2016
39
23
The Win Ratio: On Interpretation and Handling of Ties
Statistics in Biopharmaceutical Research
2020
39
24
Simultaneous Evaluation of the Magnitude and Breadth of a Left- and Right-Censored Multivariate Response, With Application to HIV Vaccine Development
Statistics in Biopharmaceutical Research
2009
37
25
Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction
Statistics in Biopharmaceutical Research
2009
36
26
Optimal Cost-Effective Go-No Go Decisions in Late-Stage Oncology Drug Development
Statistics in Biopharmaceutical Research
2009
35
27
Design and Analysis Considerations in Clinical Trials With a Sensitive Subpopulation
Statistics in Biopharmaceutical Research
2010
34
28
Comparison of Test Statistics for the Sequential Parallel Design
Statistics in Biopharmaceutical Research
2010
34
29
Strictly Standardized Mean Difference, Standardized Mean Difference and Classical
t
-test for the Comparison of Two Groups
Statistics in Biopharmaceutical Research
2010
34
30
Dose Expansion Cohorts in Phase I Trials
Statistics in Biopharmaceutical Research
2016
33
31
A Note on Good Practice of Objective Propensity Score Design for Premarket Nonrandomized Medical Device Studies with an Example
Statistics in Biopharmaceutical Research
2016
32
32
The Overlooked Importance of Constants Added in Log Transformation of Independent Variables with Zero Values: A Proposed Approach for Determining an Optimal Constant
Statistics in Biopharmaceutical Research
2018
32
33
The Current Landscape in Biostatistics of Real-World Data and Evidence: Causal Inference Frameworks for Study Design and Analysis
Statistics in Biopharmaceutical Research
2023
32
34
Stratified Wilson and Newcombe Confidence Intervals for Multiple Binomial Proportions
Statistics in Biopharmaceutical Research
2010
31
35
Bridging Solutions in Dose-Finding Problems
Statistics in Biopharmaceutical Research
2014
31
36
Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?
Statistics in Biopharmaceutical Research
2020
31
37
A Conditional Power Approach to the Evaluation of Predictive Power
Statistics in Biopharmaceutical Research
2009
30
38
A Theoretical Framework for Estimation of AUCs in Complete and Incomplete Sampling Designs
Statistics in Biopharmaceutical Research
2009
30
39
Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group
Statistics in Biopharmaceutical Research
2023
30
40
A Bayesian Design Space Approach to Robustness and System Suitability for Pharmaceutical Assays and Other Processes
Statistics in Biopharmaceutical Research
2009
28
41
Sample Size Re-estimation Designs In Confirmatory Clinical Trials—Current State, Statistical Considerations, and Practical Guidance
Statistics in Biopharmaceutical Research
2015
27
42
Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes
Statistics in Biopharmaceutical Research
2015
27
43
Borrowing From Historical Control Data in Cancer Drug Development: A Cautionary Tale and Practical Guidelines
Statistics in Biopharmaceutical Research
2019
27
44
Hypothesis Testing in a Confirmatory Phase III Trial With a Possible Subset Effect
Statistics in Biopharmaceutical Research
2009
26
45
Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical Trials
Statistics in Biopharmaceutical Research
2020
26
46
Statistical Approaches to Analyzing HIV-1 Neutralizing Antibody Assay Data
Statistics in Biopharmaceutical Research
2012
25
47
A Generalized Continual Reassessment Method for Two-Agent Phase I Trials
Statistics in Biopharmaceutical Research
2013
24
48
Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials—Application of the Estimand Framework
Statistics in Biopharmaceutical Research
2020
24
49
Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment
Statistics in Biopharmaceutical Research
2023
24
50
Global Sensitivity Analysis for Repeated Measures Studies With Informative Dropout: A Fully Parametric Approach
Statistics in Biopharmaceutical Research
2014
23
site/software ©
exaly
; All materials licenced under
CC by-SA
.